Stanley Laman Group, Ltd. Gilead Sciences, Inc. Transaction History

Stanley Laman Group, Ltd.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 17, 2023	BUY	$77.31 - $88.08 $197,449 - $224,956	2,554 New	2,554 $211,000
Q4 2020 Feb 09, 2021	SELL	$56.65 - $64.55 $182,243 - $207,657	-3,217 Closed	0 $0
Q3 2020 Oct 20, 2020	SELL	$62.1 - $78.08 $7,452 - $9,369	-120 Reduced 3.6%	3,217 $203,000
Q2 2020 Jul 20, 2020	SELL	$72.34 - $84.0 $143,450 - $166,572	-1,983 Reduced 37.27%	3,337 $257,000
Q1 2020 May 12, 2020	SELL	$62.63 - $80.22 $1.22 Million - $1.56 Million	-19,506 Reduced 78.57%	5,320 $398,000
Q4 2019 Feb 04, 2020	SELL	$61.62 - $67.78 $126,444 - $139,084	-2,052 Reduced 7.63%	24,826 $1.61 Million
Q3 2019 Nov 08, 2019	BUY	$62.51 - $69.0 $1,375 - $1,518	22 Added 0.08%	26,878 $1.7 Million
Q2 2019 Aug 01, 2019	SELL	$61.87 - $69.38 $265,112 - $297,293	-4,285 Reduced 13.76%	26,856 $1.81 Million
Q1 2019 May 10, 2019	BUY	$62.53 - $70.05 $273,756 - $306,678	4,378 Added 16.36%	31,141 $2.02 Million
Q4 2018 Feb 07, 2019	SELL	$60.54 - $79.0 $161,641 - $210,930	-2,670 Reduced 9.07%	26,763 $1.67 Million
Q3 2018 Oct 30, 2018	SELL	$71.28 - $78.92 $21,170 - $23,439	-297 Reduced 1.0%	29,433 $2.27 Million
Q2 2018 Aug 09, 2018	SELL	$64.88 - $75.68 $164,665 - $192,075	-2,538 Reduced 7.87%	29,730 $2.11 Million
Q1 2018 May 01, 2018	SELL	$72.84 - $88.8 $191,787 - $233,810	-2,633 Reduced 7.54%	32,268 $2.43 Million
Q4 2017 Feb 09, 2018	BUY	$71.15 - $83.52 $11,526 - $13,530	162 Added 0.47%	34,901 $2.5 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $2.51 Million - $2.97 Million	34,739	34,739 $2.82 Million

1,931

991M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stanley Laman Group, Ltd. with notifications on news.